 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...3637383940414243444546...170171» |
- Implanting an Extravascular ICD in Patients With a Prior Subcutaneous ICD (Zone 2, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_5112;
Abstract is embargoed at this time.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Synergistic Influence of Rivaroxaban on Platelets, Inflammation and Coagulation Biomarkers in Patients With CAD and/or PAD on Aspirin Therapy (Zone 4, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_4981;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- Savaysa (edoxaban) / Daiichi Sankyo
Association Between Oral Anticoagulant Type and Hospital Readmission Rates Following Myocardial Infarction With Percutaneous Coronary Intervention in Patients With Nonvalvular Atrial Fibrillation (Zone 4, Science and Technology Hall, Level 3; Poster Board no. 4086) - Aug 11, 2022 - Abstract #AHA2022AHA_4606;
Real-world data from two large claims databases demonstrated that post-hospitalization DOAC treatment was associated with lower hospital readmission rates than warfarin treatment in patients with NVAF who were hospitalized for MI and underwent PCI. These results thus demonstrate the value of DOAC treatment for these patients.
- QU.APS.P12. Unlocking the Future: Improving Cardiovascular Outcomes with Better Risk Prediction (Zone 3, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_4558;
- Association Of Maximum Daily Mobility After Open Cardiac Surgery And Clinical Outcomes (Zone 3, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_4556;
These results thus demonstrate the value of DOAC treatment for these patients. Abstract is embargoed at this time.
- Diagnostic Accuracy of Virtual Non-Contrast CT for Aortic Valve Stenosis Severity Evaluation (Zone 2, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_4078;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- The Significance of Tenascin C in Duschenne Muscular Dystrophy Cardiomyopathy and Fibrosis (120B) - Aug 11, 2022 - Abstract #AHA2022AHA_3772;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- Percutaneous Rebuttal (109AB) - Aug 11, 2022 - Abstract #AHA2022AHA_3709;
Abstract is embargoed at this time. There is no abstract associated with this presentation.
- Q&A (Moderated Digital Posters 4) - Aug 11, 2022 - Abstract #AHA2022AHA_3492;
There is no abstract associated with this presentation. There is no abstract associated with this presentation.
- Predictors of Primary Non-Adherence in Patients With Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the US (Moderated Posters 3) - Aug 11, 2022 - Abstract #AHA2022AHA_3265;
More than a quarter of patients experienced PMN within 30 days of an initial written OAC prescription; however, this rate decreases over a 180-day period, suggesting a delay in fills. Understanding the factors associated with no fills or delayed fills is warranted to guide interventions for improving OAC treatment rates in NVAF.
- rivaroxaban / Generic mfg.
Rivaroxaban to Improve Clinical Outcomes in Outpatients With Covid-19: A Meta-Analysis of Two Randomized Clinical Trials (Zone 2) - Aug 11, 2022 - Abstract #AHA2022AHA_3026;
P2b, P3
A patient-level meta-analysis of 2 randomized, controlled trials of similar design evaluating rivaroxaban 10 mg daily for pre-hospital prevention of thrombotic complications, hospitalization, and death in outpatients with COVID-19 will be conducted. We hope to present the results at the AHA Scientific Sessions.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Impact of Low-Dose Rivaroxaban Plus Aspirin on Total Vascular Events in Fragile Patients With Peripheral Artery Disease: Insights From VOYAGER PAD (103B) - Aug 11, 2022 - Abstract #AHA2022AHA_3737;
We hope to present the results at the AHA Scientific Sessions. Abstract is embargoed at this time.
- rivaroxaban / Generic mfg.
Rivaroxaban is a good and well-tolerated treatment for patients with livedoid vasculopathy. A Retrospective study with long-term follow-up (e-Poster Hall) - Aug 11, 2022 - Abstract #EADV2022EADV_3119;
- |||| rivaroxaban / Generic mfg.
Combination therapy, Monotherapy: Rivaroxaban Monotherapy vs Combination Therapy on Thrombotic and Bleeding Events in Atrial Fibrillation https://t.co/M7MinNkfM4 vía @JAMACardio part of @JAMANetwork. mejor monoterapia (Twitter) - Aug 11, 2022
- | rivaroxaban / Generic mfg.
Journal: Home treatment of low-risk pulmonary embolism patients : Efficacy and safety of an outpatient program including the general practitioner (Pubmed Central) - Aug 11, 2022
This study confirms the feasibility and safety of our OT program for low-risk EP patients, centered on the general practitioner. It reduces the time spent in the emergency department, reduces hospitalisations and strengthens the city-hospital link for care.
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
Clinical, Journal: Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. (Pubmed Central) - Aug 10, 2022
P3
Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.Registration: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.
- || rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
Review, Journal: Conservative treatment of peripheral arterial disease (Pubmed Central) - Aug 10, 2022
In patients with intermittent claudication exercise therapy is highly recommended. Despite the high risk, in particular patients with PAD are often undertreated in clinical practice.
- || rivaroxaban / Generic mfg., apixaban / Generic mfg.
Review, Journal: Deep vein thrombosis and pulmonary embolism : Diagnosis and treatment (Pubmed Central) - Aug 10, 2022
In cancer-associated thromboembolism (CAT), the previous guideline recommendation to use low molecular weight heparin (LMWH) for 3-6 months is now broadened with the recommendation for factor Xa inhibitors, with the caveat for gastrointestinal and urothelial cancer or expected drug-drug interactions with the anticancer treatment. Here, and in unstable clinical situations, LMWH is preferred.
- | rivaroxaban / Generic mfg., alprazolam / Generic mfg., fluoxetine / Generic mfg.
Journal: Potentially Inappropriate Medication Prescribing in Older Adults According to EU(7)-Potentially Inappropriate Medication List: A Nationwide Study in Portugal. (Pubmed Central) - Aug 10, 2022
Alprazolam and fluoxetine were mostly prescribed to older women, whereas rivaroxaban was mostly prescribed to older men. These results emphasize the need to implement initiatives and interventions to decrease PIM prescriptions in older adults.
- | rivaroxaban / Generic mfg.
Trial completion date: RITMUS-AF: Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (clinicaltrials.gov) - Aug 9, 2022
P=N/A, N=737, Active, not recruiting, Sponsor: Bayer
These results emphasize the need to implement initiatives and interventions to decrease PIM prescriptions in older adults. Trial completion date: Mar 2024 --> Sep 2022
- |||||| rivaroxaban / Generic mfg., lenalidomide / Generic mfg., apixaban / Generic mfg.
Reimbursement, Medicare: Medicare can haggle on 10 drugs in FY 2026. Seniors will have $2,000 annual cap on Rx spending. In 2020, Medicare spent more than $1 billion on almost 40 drugs, BMS’s Eliquis $9.9 bil & Revlimid $5.4 bil), & JnJ’s Xarelto $4.7 bil @Transplant_Doc https://t.co/PCCovRtdkE (Twitter) - Aug 9, 2022
- | warfarin / Generic mfg.
Journal: Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study. (Pubmed Central) - Aug 7, 2022
Trial completion date: Mar 2024 --> Sep 2022 Warfarin treatment was associated with higher rates of clinically relevant epistaxis compared to direct oral anticoagulants.
- | rivaroxaban / Generic mfg.
Preclinical, Journal: Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes. (Pubmed Central) - Aug 7, 2022
Danshen tablet inhibits the metabolism of rivaroxaban, which may be because its lipid-soluble components such as dihydrotanshinone I strongly inhibit the activities of CYP enzymes, especially CYP3A and CYP2J. Therefore, when Danshen tablet and rivaroxaban are used simultaneously in the clinic, it is necessary to strengthen the drug monitoring of rivaroxaban and adjust the dosage.
- | Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Preclinical, Journal: In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra. (Pubmed Central) - Aug 6, 2022
Especially heparin-free 4F-PCC also improved clot stability against fibrinolytic breakdown. Beriplex/Kcentra contains heparin, and this may have caused reduced effectivity compared to Cofact.
- | rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Journal: Heparin-induced thrombocytopenia post-cardiovascular interventional therapy: a case report. (Pubmed Central) - Aug 6, 2022
This case emphasizes the significance of suspecting HIT in patients with unexplained rapid thrombocytopenia after frequent heparin exposure. Decision-making regarding alternative anticoagulation and platelet transfusion in HIT with hemorrhage must be based on unique patient characteristics.
- ||| rivaroxaban / Generic mfg.
Generic launch: Bayer's Xarelto continues to feel the pressure from generics. On the flipside, new launches are thriving. https://t.co/a6LE86NrQI (Twitter) - Aug 5, 2022
- || rivaroxaban / Generic mfg., fondaparinux / Generic mfg.
Retrospective data, Review, Journal: Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach. (Pubmed Central) - Aug 5, 2022
Decision-making regarding alternative anticoagulation and platelet transfusion in HIT with hemorrhage must be based on unique patient characteristics. This NMA confirms the favorable benefit/risk ratio of thromboprophylaxis for patients with leg immobilization after trauma with the highest level of evidence for rivaroxaban.
- | rivaroxaban / Generic mfg.
Journal: Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. (Pubmed Central) - Aug 4, 2022
In the 336 (10.3%) patients with a reduced dose NOAC recommendation, 22.9% were overdosed, most often with rivaroxaban...In newly diagnosed Dutch AF patients, off-label dosing of NOACs was seen in only 6.6% of patients, most often underdosing. In this study, determinants of off-label dosing were age, renal function, weight, anaemia, active malignancy, and concomitant use of antiplatelets.
- | rivaroxaban / Generic mfg.
New P4 trial: SHORT RUN AF: Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk (clinicaltrials.gov) - Aug 4, 2022
P4, N=550, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
Trial completion: A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin (clinicaltrials.gov) - Aug 4, 2022
P=N/A, N=32000, Completed, Sponsor: Boehringer Ingelheim
In this study, determinants of off-label dosing were age, renal function, weight, anaemia, active malignancy, and concomitant use of antiplatelets. Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Clinical, Journal, HEOR: Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. (Pubmed Central) - Aug 4, 2022
Four weeks of postdischarge VTE prophylaxis results in higher QALYs compared with inpatient prophylaxis alone and prevents 1 postdischarge VTE among 78 patients with IBD. Although postdischarge VTE prophylaxis for all patients with IBD is not cost-effective, it should be considered in a case-by-case scenario, considering VTE risk profile, costs, and patient preference.
- || rivaroxaban / Generic mfg., aspirin / Generic mfg., dabigatran etexilate / Generic mfg.
Review, Journal: Review and update of the concept of embolic stroke of undetermined source. (Pubmed Central) - Aug 4, 2022
The neutral results of the trials of anticoagulation and insights into ESUS from research conducted since the concept was introduced warrant reassessment of the ESUS construct as a research concept and a treatment target. In this Review, we discuss the evidence produced since the concept of ESUS was introduced, and propose updates to the criteria and diagnostic algorithm in light of the latest knowledge.
- || Savaysa (edoxaban) / Daiichi Sankyo
Retrospective data, Review, Journal, HEOR: Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. (Pubmed Central) - Aug 3, 2022
The pooling results produced moderate to high heterogeneity particularly in UMICs. Further studies are required to inform UMICs with SP.
- | rivaroxaban / Generic mfg.
Retrospective data, Journal: Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study. (Pubmed Central) - Aug 3, 2022
Logistic univariate and multivariate analysis showed that baseline hs-CRP level (OR = 1.10, 95%CI: 1.05-1.34), lesion length (OR = 1.04, 95%CI: 1.02-1.27), use of rivaroxaban (OR = 1.08, 95%CI: 1.05-1.39), NLR (OR = 1.47, 95%CI: 1.13-2.48), LDL-C level (OR = 1.25, 95%CI: 1.05-1.52), and diabetes (OR = 1.25, 95%CI: 1.05-1.52) = 1.18, 95%CI: 1.06-1.66) were predictors of restenosis. Baseline NLR before DCB can predict the risk of restenosis after surgery.
- || Savaysa (edoxaban) / Daiichi Sankyo
Retrospective data, Review, Journal: Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis. (Pubmed Central) - Aug 2, 2022
Furthermore, the pooled estimates of the Child-Turcotte-Pugh (CTP) class indicated that DOACs reduced the incidence of all bleeding (RR: 0.61; 95%CI: 0.45 to 0.82), gastrointestinal bleeding (RR 0.55; 95%CI: 0.37 to 0.83), and all-cause death (RR: 0.62; 95%CI: 0.49 to 0.79) in patients with mild to moderate cirrhosis. Our study demonstrates that DOACs significantly reduce the risk of bleeding in patients with liver disease compared with warfarin/LMWH.
- || rivaroxaban / Generic mfg., apixaban / Generic mfg.
So no apixaban and no rivaroxaban. Has apixaban done a medically ILL trial? (Twitter) - Aug 2, 2022
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: EPCATIII: VTE Prevention Following Total Hip and Knee Arthroplasty (clinicaltrials.gov) - Aug 1, 2022
P3, N=5400, Recruiting, Sponsor: Sudeep Shivakumar
Our study demonstrates that DOACs significantly reduce the risk of bleeding in patients with liver disease compared with warfarin/LMWH. Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | rivaroxaban / Generic mfg.
Journal: Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. (Pubmed Central) - Jul 30, 2022
Recent NIH and ISTH guidelines recommend or suggest this approach. Results from other clinical trials are pending.
- | Journal: Drugs for treatment and prevention of venous thromboembolism. (Pubmed Central) - Jul 30, 2022
Results from other clinical trials are pending. No abstract available
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Comparison table: Some oral anticoagulants for VTE. (Pubmed Central) - Jul 30, 2022
No abstract available No abstract available
- || Clinical data, Journal: Clinical Outcome of Different Postoperative Prophylactic Strategies on Symptomatic Venous Thromboembolism after Total Knee Arthroplasty. (Pubmed Central) - Jul 30, 2022
The observed incidence of symptomatic VTE in this study was similar to previous studies regardless of the type of post-operative inpatient or outpatient prophylaxis prescribed. The ultimate choice of prophylaxis should remain with the treating physician and their knowledge of a particular patient's medical history.
- || Savaysa (edoxaban) / Daiichi Sankyo
Review, Journal: Current Antithrombotic Therapy Strategies in Children with a Focus on Off-Label Direct Oral Anticoagulants-A Narrative Review. (Pubmed Central) - Jul 29, 2022
(4) Dabigatran and rivaroxaban could be valid therapeutic options for VTE management in children. In the case of apixaban and edoxaban, results from ongoing clinical studies are required before using them in pediatric VTE.
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Pricing: For as long as the government pays $600+/mo at list price for every prescription drug in America, worrying about CMS’ budget concerns is my very lowest priority. Want to pay for the AF ablation? Negotiate half off your millions of purchases of Xarelto or Eliquis. (Twitter) - Jul 29, 2022
- ||| rivaroxaban / Generic mfg.
Journal, Adverse events: Risks in Induction of Platelet Aggregation and Enhanced Blood Clot Formation in Platelet Lysate Therapy: A Pilot Study. (Pubmed Central) - Jul 29, 2022
Moreover, heparin- and rivaroxaban-added PL groups demonstrated no clot formation in ROTEM assays. Platelet lysate-induced hypercoagulability was demonstrated in vitro in the present study, which could be prevented by fibrinogen depletion or the addition of an anticoagulant.
- || rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Retrospective data, Review, Journal: Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery-Systematic Review and Meta-Analysis. (Pubmed Central) - Jul 29, 2022
However, regarding the safety variable, no significant difference was found between the incidence of major bleeding in rivaroxaban and enoxaparin (RR = 0.97; 95% CI = 0.56-1.68). The results of the analysis show that rivaroxaban has better efficacy than enoxaparin but the same safety profile, so when used, the bleeding of patients should still be monitored.
- | Savaysa (edoxaban) / Daiichi Sankyo
Observational data, Journal: Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study. (Pubmed Central) - Jul 29, 2022
The sensitivity to detect clinically relevant drug concentrations was 85.1% in the case of 30 µg L (95% CI 82.0, 87.7; specificity 77.9; 72.1, 82.7), 85.7% in the case of 50 µg L (82.4, 88.4; specificity 77.3; 72.5, 81.5), and 85.1% in the case of 100 µg L (80.9, 88.4; specificity 73.2%; 69.1, 76.9). In conclusion, the association of PiCT with DOAC concentrations was fair, and the majority of clinically relevant drug concentrations were correctly predicted.
- | diltiazem / Generic mfg.
Retrospective data, Journal: Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation. (Pubmed Central) - Jul 29, 2022
Conclusions Concomitant use of diltiazem with DOACs was associated with a higher bleeding risk in patients with atrial fibrillation, consistently in both subgroups of chronic kidney disease and non-chronic kidney disease. For DOAC users, concomitant diltiazem should be prescribed only when the benefit outweighs the risk, with close monitoring for signs of bleeding.
- rivaroxaban / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: ACCOG: AntiCoagulants and COGnition (clinicaltrials.gov) - Jul 27, 2022
P4, N=48, Recruiting, Sponsor: University Hospital, Angers
For DOAC users, concomitant diltiazem should be prescribed only when the benefit outweighs the risk, with close monitoring for signs of bleeding. Unknown status --> Recruiting | Trial completion date: Mar 2021 --> Feb 2023 | Trial primary completion date: Mar 2021 --> Feb 2023
- || rivaroxaban / Generic mfg., apixaban / Generic mfg.
Enrollment closed, Real-world evidence, Head-to-Head, Real-world: An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism) (clinicaltrials.gov) - Jul 27, 2022
P=N/A, N=2000, Active, not recruiting, Sponsor: Bayer
Unknown status --> Recruiting | Trial completion date: Mar 2021 --> Feb 2023 | Trial primary completion date: Mar 2021 --> Feb 2023 Not yet recruiting --> Active, not recruiting
- || warfarin / Generic mfg.
Clinical, Journal: Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device. (Pubmed Central) - Jul 27, 2022
Not yet recruiting --> Active, not recruiting The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after Watchman device implantation in a Chinese population.